DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle Et Al USOO9376418B2 (12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle et al. (45) Date of Patent: Jun. 28, 2016 (54) SUBSTITUTED PYRIDINE SPLEEN 31/5377 (2013.01); A61K3I/5383 (2013.01); TYROSINE KINASE (SYK) INHIBITORS A61 K3I/551 (2013.01); A61K 45/06 (2013.01); C07D401/14 (2013.01); C07D (71) Applicants: Merck Sharp & Dohme Corp., 405/14 (2013.01); C07D 409/14 (2013.01); Rahway, NJ (US); Merck Canada Inc., C07D 413/14 (2013.01); C07D 417/14 Kirkland, Quebec (CA) (2013.01); C07D 471/04 (2013.01); (Continued) Inventors: (72) Andrew M. Haidle, Cambridge, MA (58) Field of Classification Search (US); Sandra Lee Knowles, Princeton, CPC ............... CO7D 401/12: CO7D 401/14: A61 K NJ (US); Solomon D. Kattar, Arlington, 31/5377; A61K31/506 MA (US); Denis Deschenes, Lachine USPC ........................ 544/122, 331; 514/235.8, 275 (CA); Jason Burch, Redwood City, CA See application file for complete search history. (US); Joel Robichaud, Dollard-des-Ormeaux (CA); Matthew (56) References Cited Christopher, Brookline, MA (US); Michael D. Altman, Needham, MA U.S. PATENT DOCUMENTS (US); James P. Jewell, Newtown, MA 5,710,129 A 1/1998 Lynch et al. (US); Alan B. Northrup, Reading, VA 6/2001 Uckun et al. (US); Marc Blouin, Saint-Lazare (CA); 6,248,790 B1 John Michael Ellis, Needham, MA (Continued) (US); Hua Zhou, Acton, MA (US); Christian Fischer, Natick, MA (US); FOREIGN PATENT DOCUMENTS Adam J. Schell, Decatur, GA (US); EP 877O2O A1 11, 1998 Michael H. Reutershan, Brookline, MA EP 2441755 A1 4/2012 (US); Brandon M. Taoka, Hoboken, NJ (US); Anthony Donofrio, Cambridge, (Continued) MA (US) OTHER PUBLICATIONS Assignees: Pearce et al., Failure modes in anticancer drug discovery and devel (73) Merck Sharp & Dohme Corp., opment, Cancer Drug Design and Discovery Edited by Stephen Rahway, NJ (US); Merck Canada Inc., Neidle, Chapter 18, pp. 424-435 (2008).* Kirkland, Quebec (CA) Johnson et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, British Journal of (*) Notice: Subject to any disclaimer, the term of this Cancer (2001) 64(10): 1424-1431.* patent is extended or adjusted under 35 Simone. Oncology: Introduction, Cecil Textbook of Medicine, 20th U.S.C. 154(b) by 13 days. Edition, vol. 1, pp. 1004-1010, 1996.* (Continued) (21) Appl. No.: 14/409,151 Primary Examiner — Deepak Rao (22) PCT Fled: Jun. 17, 2013 (74) Attorney, Agent, or Firm — Eric A. Meade: Anna L. (86) PCT NO.: PCT/US2O13/046151 CocuZZO S371 (c)(1), (57) ABSTRACT (2) Date: Dec. 18, 2014 The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, (87) PCT Pub. No.: WO2O13/192098 wherein R. R. R. R. R. C., and t are as defined herein. PCT Pub. Date: Dec. 27, 2013 The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the com (65) Prior Publication Data pounds for treating diseases or conditions mediated by Spleen US 2015/O 1483.27 A1 May 28, 2015 Tyrosine Kinase (Syk) kinase. Related U.S. Application Data (I) (RC), (60) Provisional application No. 61/663,290, filed on Jun. 22, 2012. (O R2 R3 (51) Int. C. 21 NN CO7D 40/12 (2006.01) CO7D 40/4 (2006.01) NN 1. N (Continued) H (52) U.S. C. CPC ............ C07D401/12 (2013.01); A61K3I/505 (2013.01); A61 K3I/506 (2013.01); A61 K 18 Claims, No Drawings US 9,376.418 B2 Page 2 (51) Int. Cl. 2011/0301 175 A1 12/2011 Molteni et al. A6 IK3I/506 (2006.01) 2014/0148474 A1 5/2014 Altman et al. A 6LX3L/505 2006.O1 2014/0243336 A1 8/2014 Altman et al. (2006.01) 2014/0249 130 A1 9, 2014 Deschenes et al. A6 IK 45/06 (2006.01) 2015, 0166486 Al 6, 2015 Haidle et al. A 6LX3/5377 (2006.01) 2015,0175575 A1 6, 2015 Lim et al. A6 IK3I/5383 (2006.01) 33.85: A 58 NE A6 IK3I/55 (2006.01) CO7D 405/4 (2006.01) FOREIGN PATENT DOCUMENTS CO7D 413/4 (2006.01) CO7D 417/4 (2006.01) JP 20042O3748 12/2002 CO7D 47L/04 (2006.01) WO WOO3078.404 A1 9, 2003 CO7D 47L/TO (2006.01) WO WO2004080463 A1 9, 2004 CO7D 487/04 (2006.015 WO WO2005O13996 A2 2, 2005 WO WO2O06093247 A1 2, 2005 C07D 491/107 (2006.01) WO WO2005O26158 A1 3, 2005 CO7D 49 I/II3 (2006.01) WO WO2005033103 A1 4, 2005 CO7D 49.8/04 (2006.01) W: Woo: A 39. C E. 3:08: WO WO2006050480WO2006O28833 A2A1 3f20065, 2006 CO7D 487/10 (2006.01) WO WO200606877O A1 6, 2006 (52) U.S. Cl WO WO2006078846 A1 T 2006 AV e. we WO WO2006129 100 A1 12/2006 CPC ........... C07D 471/10 (2013.01); C07D487/04 WO WO2006133426 A2 12/2006 (2013.01); C07D 487/10 (2013.01); C07D WO WO2006135915 A2 12/2006 491/08 (2013.01); C07D491/107 (2013.01); WO WO2007OO9681 A1 1, 2007 C07D491/113 (2013.01); C07D498/04 WO WO2007OO9773 A1 1, 2007 (2013.01) WO WO2007028445 A1 3, 2007 WO WO2007042298 A1 4/2007 WO WO2007042299 A1 4/2007 (56) References Cited WO WO2007070872 A1 6, 2007 WO WO2007085540 A1 8, 2007 U.S. PATENT DOCUMENTS WO WO2007 120980 A2 10/2007 WO WO2009084695 A1 12/2007 6.432,963 B1 8/2002 Hisamichi et al. WO WO2009031011 A2 3, 2009 6,552,029 B1 4/2003 Davis et al. WO WO2009097287 A1 8, 2009 6,589,950 B1 7/2003 Hayler et al. WO WO2009102468 A1 8, 2009 6,770,643 B2 8, 2004 Cox et al. WO WO2009 131687 A2 10/2009 6,797,706 B1 9, 2004. Hisamichi et al. WO WO2009 136995 A2 11/2009 6,897,207 B2 5, 2005 Cox et al. WO WO2O0914585.6 A1 12/2009 6,897,208 B2 5, 2005 Edwards et al. WO WO2O10068257 A1 6, 2010 6,911,443 B2 6, 2005 Yura et al. WO WO2O10068258 A1 6, 2010 7,060,827 B2 6/2006 Singh et al. WO 2011 O75515 A1 6, 2011 7,122,542 B2 10/2006 Singh et al. WO WO2O14031438 A2 2, 2014 7,259,154 B2 8, 2007 Cox et al. OTHER PUBLICATIONS 7.276,502 B2 10/2007 Brenchley et al. Gura, Systems for identifying New Drugs Are Often Faulty, Cancer 7,803,801 B2 9/2010 Kodama et al. Models, Science, vol. 278, No. 5340, pp. 1041-1042, Nov. 1997.* 5. g R: 1933 AA et Pamuk et al., Spleen tyrosine kinase inhibition in the treatment of 8,759,366- - B2 6, 2014 Childerstman et et al. al. autoimmune, allergic and autoinflammatoryck diseases, Arthritis 8,796.310 B2 8, 2014 R. tal Research & Therapy, (2010), 12:222, pp. 1-11. - w OO a International Search Report and Written Opinion for PCT/US 13/ 8.987,456 B2 3/2015 Altman et al. 46151 illed on Nov. 1, 2013 9,006,444 B2 4/2015 Altman et al. is mailed on Nov. 1, . 9,120,785 B2 9, 2015 Altman et al. Villasenor et al., Structural Insights for Design of Potent Spleen 2004.00299.02 A1 2/2004 Singh et al. Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three 2004.0054179 A1 3, 2004 Yura et al. Inhibitor Complexes,& 8 Chem Biol Drug Des. 2009, 466-470, 73. 2006, O135543 A1 6/2006 Singh et al. Yamamoto et al, The Orally Available Spleen Tyrosine Kinase 2006/01784.07 A1 8/2006 Argade et al. inhibitor (2-7-(3,4-Dimethoxyphenyl)imidazo[12-elpyrimidin-5- 2006/0211657 A1 9/2006 Singh et al. ylaminol-nicotinamide Dihydrochloride (BAY 6 1.3606) Blocks 2006/0234483 A1 10, 2006 Arak et al. Antigen-Induced Airway. Inflammation in Rodents , The Journal of 2006/0247262 A1 11/2006 Baenteli et al. Pharmacology and Experimental Therapeutics, 2003, pp. 1174-1181. 2007/0004626 A1 1/2007 Masuda et al. vol. 306(3). 2007/0129362 A1 6/2007 Bhamidipati et al. European Search Report for PCT/US2013/046151 mailed Nov. 18, 2007/O197782 A1 8/2007 Clough et al. 2015. 2008, 0221171 A1* 9, 2008 Eberle et al. .................. 514,352 2011/0245205 A1 10, 2011 Altman et al. * cited by examiner US 9,376,418 B2 1. 2 SUBSTITUTED PYRIDINE SPLEEN mediators and spasmogens (Wong et al. 2004, Expert Opin. TYROSINE KINASE (SYK) INHIBITORS Investig. Drugs (2004) 13 (7) 743-762). Recently, it has been shown that the Syk kinase inhibitor CROSS REFERENCE TO RELATED R112 (Rigel), dosed intranasally in a phase I/II study for the APPLICATIONS treatment of allergic rhinitis, gave a statistically significant decrease in PGD, a key immune mediator that is highly This application is a U.S. National Phase application under correlated with improvements in allergic rhinorrhea, as well 35 U.S.C. S371 of PCT Application No. PCT/US2013/ as being safe across a range of indicators, thus providing the 046151, filed Jun. 17, 2013, which claims priority under 35 first evidence for the clinical safety and efficacy of a topical U.S.C. S 119(e) from U.S. Provisional Application No. 10 Syk kinase inhibitor. (Meltzer, Eli O.; Berkowitz, Robert B.: 61/663,290, filed Jun. 22, 2012. Grossbard, Elliott B. Journal of Allergy and Clinical Immu nology (2005), 115(4), 791-796). In a more recent phase II FIELD OF THE INVENTION clinical trial for allergic rhinitis (Clinical Trials.gov Identifier NCT0015089). R112 was shown as having a lack of efficacy The present invention relates to certain substituted pyridine 15 Versus placebo. Rheumatoid Arthritis (RA) is an auto-immune disease compounds of the Formula (I) (also referred to herein as the affecting approximately 1% of the population.
Load more

Recommended publications
  • PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 Mg/Ml Β2-Adrenergic Stimulant Bronchodilator AA P
    PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 mg/mL 2-Adrenergic Stimulant Bronchodilator AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 10, 2014 Vaughan, Ontario L4K 4N7 Control Number: 172362 1 PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulfate Syrup House Standard 2 mg/mL THERAPEUTIC CLASSIFICATION 2–Adrenergic Stimulant Bronchodilator ACTIONS AND CLINICAL PHARMACOLOGY Orciprenaline sulphate is a bronchodilating agent. The bronchospasm associated with various pulmonary diseases - chronic bronchitis, pulmonary emphysema, bronchial asthma, silicosis, tuberculosis, sarcoidosis and carcinoma of the lung, has been successfully reversed by therapy with orciprenaline sulphate. Orciprenaline sulphate has the following major characteristics: 1) Pharmacologically, the action of orciprenaline sulphate is one of beta stimulation. Receptor sites in the bronchi and bronchioles are more sensitive to the drug than those in the heart and blood vessels, so that the ratio of bronchodilating to cardiovascular effects is favourable. Consequently, it is usually possible clinically to produce good bronchodilation at dosage levels which are unlikely to cause cardiovascular side effects. 2 2) The efficacy of the bronchodilator after both oral and inhalation administration has been demonstrated by pulmonary function studies (spirometry, and by measurement of airways resistance by body plethysmography). 3) Rapid onset of action follows administration of orciprenaline sulphate inhalants, and the effect is usually noted immediately. Following oral administration, the effect is usually noted within 30 minutes. 4) The peak effect of bronchodilator activity following orciprenaline sulphate generally occurs within 60 to 90 minutes, and this activity lasts for 3 to 6 hours. 5) Orciprenaline sulphate taken orally potentiates the action of a bronchodilator inhalant administered 90 minutes later, whereas no additive effect occurs when the drugs are given in reverse order.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • ADD/ADHD: Strattera • Allergy/Anti-Inflammatories
    EXAMPLES OF PERMITTED MEDICATIONS - 2015 ADD/ADHD: Strattera Allergy/Anti-Inflammatories: Corticosteroids, including Decadron, Depo-Medrol, Entocort, Solu-Medrol, Prednisone, Prednisolone, and Methylprednisolone Anesthetics: Alcaine, Articadent, Bupivacaine HCI, Chloroprocaine, Citanest Plain Dental, Itch-X, Lidocaine, Marcaine, Mepivacaine HCI, Naropin, Nesacaine, Novacain, Ophthetic, Oraqix, Paracaine, Polocaine, Pontocaine Hydrochloride, PrameGel, Prax, Proparacaine HCI, Ropivacaine, Sarna Ultra, Sensorcaine, Synera, Tetracaine, Tronothane HCI, and Xylocaine Antacids: Calci-Chew, Di-Gel, Gaviscon, Gelusil, Maalox, Mintox Plus, Mylanta, Oyst-Cal 500, Rolaids, and Tums Anti-Anxiety: Alprazolam, Atarax, Ativan, Buspar, Buspirone HCI, Chlordiazepoxide HCI, Clonazepam, Chlorazepate Dipotassium, Diastat, Diazepam, Hydroxyzine, Klonopin, Librium, Lorazepam, Niravam, Tranxene T-tab, Valium, Vistaril, and Xanax Antibiotics: Acetasol HC, Amoxil, Ampicillin, Antiben, Antibiotic-Cort, Antihist, Antituss, Avelox, Ceftazidime, Ceftin, Cefuroxime Axetil, Ceptaz, Cleocin, Cloxapen, Cortane-B Aqueous, Cortic, Cresylate, Debrox, Doryx, EarSol-HC, Fortaz, Gantrisin, Mezlin, Moxifloxacin, Neotic, Otocain, Principen, Tazicef, Tazidime, Trioxin, and Zyvox Anti-Depressants: Adapin, Anafranil, Asendin, Bolvidon, Celexa, Cymbalata, Deprilept, Effexor, Elavil, Lexapro, Luvox, Norpramin, Pamelor, Paxil, Pristiq, Prozac, Savella, Surmontil, Tofranil, Vivactil, Wellbutrin, Zoloft, and Zyban Anti-Diabetics: Actos, Amaryl, Avandia, Glipizide, Glucophage,
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Clinical Trial of Orciprenaline in Bradyarrhythmias
    100 SINGAPORE MEDICAL JOURNAL Vol. 16, No. 2. June, 1975. CLINICAL TRIAL OF ORCIPRENALINE IN BRADYARRHYTHMIAS By Chin Hock, Lirn, Charles C. S. Toh and Oon Teik, Khoo SYNOPSIS The intravenous and oral forms of orciprenaline was used in the treatment of patients with severe sinus bradycardia, high grade atrio -ventricular block or the sick sinus syndrome. Intra- venous orciprenaline can be used to tide patients over a period of severe bradyarrhythmia, or prior to cardiac pacing. One patient developed ventricular tachycardia following an intravenous bolus of orciprenaline. Oral orciprenaline was used in 23 patients with severe bradyarrhythmia. Two patients responded poorly to it. Saventrine was given sequentially in nine patients. The merits and side effects of both drugs are discussed. INTRODUCTION efficiency of orciprenaline and to compare it with Saventrine in the treatment of complete In 1952, Nathanson and Miller introduced heart block and other forms of bradyarrhyth- isoprenaline for the treatment of heart block and mias. it still has an important role in the treatment of bradyarrhythmias. Nis Innissen and Thompson PHARMACOLOGY (1965) felt that the use of a sustained release form of isoprenaline could reduce the need for Orciprenaline (Alupent*) is a derivative of pacemakers. Intravenous isoprenaline and orci- isoprenaline but it has predominant beta -two prenaline may be used to treat patients with stimulatine effects and is commonly used as a Stokes Adams (S.A.) attacks resulting from very bronchodilator (Bogdan, 1969). However, it has slow ventricular rates in acute myocardial chronotropic and inotropic effects. It stimulates infarction, either alone or prior to cardiac the sino -atrial and atrioventricular nodes and pacing.
    [Show full text]
  • Orciprenaline Sulphate (Alupent): Planned Withdrawal from the UK Market Following a Risk-Benefit Analysis
    MHRA PUBLIC ASSESSMENT REPORT Orciprenaline sulphate (Alupent): planned withdrawal from the UK market following a risk-benefit analysis November 2009 Executive summary 2 1. Introduction 3 2. Summary of data 3 2.1 Clinical pharmacology 3 2.2 Efficacy 3 2.3 Safety 4 3. Conclusions 8 4. References 9 5. Glossary 10 1 EXECUTIVE SUMMARY (Please note that this summary is intended to be accessible to all members of the public, including health professionals) Background The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency responsible for regulating the effectiveness and safety of medicines and medical devices in the UK. We continually review the safety of all medicines in the UK, and inform healthcare professionals and the public of the latest safety updates. In our Public Assessment Reports, we discuss the evidence for a safety issue with a particular drug or drug class, and changes made to the product information for the drug on the basis of this evidence, which will help safeguard public health. This MHRA Public Assessment Report discusses a review of the risks and benefits of a medicine called orciprenaline sulphate. Orciprenaline sulphate is available for oral administration as a syrup used to treat reversible airways obstructiona, which is a symptom of asthmab and chronic obstructive pulmonary diseasec. It acts on specific areas in the body called β- receptors, which relaxes the muscles used for breathing and opens the airways in the lungs. Orciprenaline sulphate was licensed in 1972 and is marketed in the UK under the brand name Alupent Syrup. As with any medicine, the use of orciprenaline sulphate may lead to adverse reactions (side-effects) in some individuals, which are described in the product information, including the patient information leaflet (see the Electronic Medicines Compendium (product information) website).
    [Show full text]
  • Sympathoadrenergic Modulation of Hematopoiesis: a Review of Available Evidence and of Therapeutic Perspectives
    REVIEW published: 05 August 2015 doi: 10.3389/fncel.2015.00302 Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives Marco Cosentino*, Franca Marino and Georges J. M. Maestroni Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy Innervation of the bone marrow (BM) has been described more than one century ago, however the first in vivo evidence that sympathoadrenergic fibers have a role in hematopoiesis dates back to less than 25 years ago. Evidence has since increased showing that adrenergic nerves in the BM release noradrenaline and possibly also dopamine, which act on adrenoceptors and dopaminergic receptors (DR) expressed on hematopoietic cells and affect cell survival, proliferation, migration and engraftment ability. Remarkably, dysregulation of adrenergic fibers to the BM is associated with hematopoietic disturbances and myeloproliferative disease. Several adrenergic and dopaminergic agents are already in clinical use for non-hematological indications and with a usually favorable risk-benefit profile, and are therefore potential candidates for Edited by: non-conventional modulation of hematopoiesis. Wanda Lattanzi, Università Cattolica del Sacro Cuore, Keywords: dopamine, noradrenaline, adrenaline, adrenoceptors, dopaminergic receptors, hematopoiesis, Italy neuroimmune phamacology, drug repurposing Reviewed by: Sujit Basu, Introduction Ohio State University, USA Tsvee Lapidot, Weizmann Institute of Science, Israel The term ‘‘niche’’, derived from the Latin word ‘‘mytilus’’ (mussel), has eventually come to designate a shallow recess in a wall, as for a statue or other decorative object, in view of the *Correspondence: similarity with the shape of a seashell, and broadly a place suitable or appropriate for a person or Marco Cosentino, Center for Research in Medical thing.
    [Show full text]
  • UV-Vis-5-Compressed.Pdf
    Ultraviolet and visible spectroscopy David G. Watson Lecture 5 EMADALSAMARRAI Fig.4.13 The complex formed between adrenaline and iron, which is used to analyse adrenaline at low levels in an injection. Adrenaline iron (ll) complex l'iiiitl.iiitiliiiil Self-test 4.7 iiri:lilllr:i!!!f !!:ill Adrenaline in bupivacaine/adrenaline injection is assayed by complex formation with iron (ll). 20 ml of the injection is mixed with 0.2 ml of reagent and 2 ml of buffer and a reading istaken in a 4 cm pathlength cell. A reading of a solution containing 5.21 pglml of adrenaline is taken under the same conditions. The following results were obtained: . Absorbance of sample:0.173 . Absorbance of standard solution:0.18i Calculate the percentage of w/v of adrenaline in the injection. t n/rvr %s000'0 :JaMsuv Difference spectrop hotometry In difference spectroscopy, a component in a mixture is analysed by carrying out a reaction which is selective for the analyte. This could be simply bringing about a shift in wavelength through adjustment of the pH of the solution in which the analyte is dissolved or a chemical reaction such as oxidation or reduction. In the following example the selective alkaline shift of aspirin is used to determine it in a preparation also containing dextropropoxyphene, naphthalene sulphonic acid and caffeine. Caffeine, dextropropoxyphene and the naphthalene sulphonic acid anion do not undergo appreciable alkaline shifts whereas aspirin does. Figure 4.14A shows the spectrum of the extract from tablets in 0.1 M HCI - in fact there is relatively minor interference at the wavelength used for the determination of aspirin but by using the sample in HCI in place of a blank in the reference cell one can be sure that interference from the excipients is eliminated.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Drug Index and Glossary
    Drug index and glossary Approved name Proprietary name Proprietary name Page (UK) (USA) number Acebutolol Sectral Sectral 101 Acetaminophen (see Paracetamol) Actinomycin Cosmegen Lyovac 21 Acyclovir Zovirax Zovirax 30, 65-6, 156, 159,281 Adenosine triphosphate 233 Adrenaline 72, 78, 262, 263, (epinephrine) 264,265 Alcohol (see Ethanol) Aloes 48 Aluminium hydroxide Alu-Cap Many preparations 90 Aludrox available Ambroxol 39,143 Amikacin Amikin Amikin 29,152,167,168, 184-6,281 Aminophylline Pecram Mudrane 30,39,133,134, Phyllocontin Somophylline 143,283 Continus Theodrox Aminosalicylic acid 154, 168, 198, (para-aminosalicylic 203-4 acid) Amiodarone Cordarone Cordarone 24 Amoxycillin Almodan Trlmox 152, 154, 155, (amoxicillin) Amoxil Wymox 160, 161, 162, 166,167, 171-2, 192, 281 Amphotericin Fungilin 'Fungizone' 168, 207--S, 281 Fungizone Ampicillin Ampifen Omnipen 47,162,16,167, Penbritin Principen 281 Vidopen Unasyn Amylobarbitone Amytal 108,125 (amobarbital) Antitetanus Humotet Hyper-Tet 53,54-5 immunoglobulin Antivaccinial gamma 51,58 globulin Drug index and glossary 289 Approved name Proprietary name Proprietary name Page (UK) (USA) number Antivaricella-zoster 65 immunoglobulin Apomorphine 97 Arnica 278 Ascorbic acid Redoxon Many preparations 70,75--6 available Aspirin Many preparations Many preparations 23,48,99,100, available available 141,272-3,276 Atebrin 12 (Atabrine, Medacrine, Quinacrine) Atenolol Tenormin Tenormin 101,120 Atropine Many combined Many combined 48,49,96,222, preparations preparations 234,250,26S-9 available available
    [Show full text]